Brief: Otsuka Pharmaceutical And H. Lundbeck Say U.S. FDA Accepted New Drug Application For Aripiprazole Injectable To Treat Adult Schizophrenia And Bipolar I Disorder
Sept 13 (Reuters) -
* OTSUKA PHARMACEUTICAL AND H. LUNDBECK SAY U.S. FDA
ACCEPTED NEW
DRUG APPLICATION FOR ARIPIPRAZOLE INJECTABLE TO TREAT ADULT
SCHIZOPHRENIA AND BIPOLAR I DISORDER
Further company coverage: 4578.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on H Lundbeck A/S
See all newsUBS upgrades Lundbeck to 'buy' on high epilepsy drug conviction
DB downgrades Lundbeck to 'sell' on Rexulti patent cliff risk
Europe Research Roundup: ASM International, Michelin, Nokian Renkaat
Europe Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Europe Research Roundup: BMW, Fugro, Mercedes-Benz